Asciminib provides durable responses and a favorable safety profile in patients with chronic myeloid leukemia (CML) in chronic phase (CP) with the T315I mutation in a phase 1 study Meeting Abstract
| Authors: | Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Réa, D.; Goh, Y. T.; Janssen, J. J. W. M.; Heinrich, M. C.; Talpaz, M.; Etienne, G.; Breccia, M.; Deininger, M.; le Coutre, P.; Lang, F.; Polydoros, F.; Cacciatore, S.; Stenson, L.; Kim, D. W. |
| Abstract Title: | Asciminib provides durable responses and a favorable safety profile in patients with chronic myeloid leukemia (CML) in chronic phase (CP) with the T315I mutation in a phase 1 study |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cml; asciminib; t315i |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S335 |
| End Page: | S336 |
| Language: | English |
| ACCESSION: | WOS:000691910500222 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01784-5 |
| Notes: | Meeting Abstract: CML-413 -- Source: Wos |
